Correlation Between Use of Antiretroviral Adherence Devices by HIV-Infected Youth and Plasma HIV RNA and Self-Reported Adherence
Tóm tắt
Our objective was to investigate antiretroviral adherence device use by HIV-infected youth and assess associations of device use with viral suppression and self-reported adherence. This cross-sectional, multisite, clinic-based study included data from 1,317 HIV-infected individuals 12–24 years of age that were prescribed antiretroviral therapy. Mean adherence in the past 7 days was 86.1 % and 50.5 % had an undetectable HIV RNA. Pillbox was the most commonly endorsed device. No specific device was independently associated with higher odds of 100 % adherence. Paradoxically, having an undetectable HIV RNA was inversely associated with use of adherence devices (OR 0.80; p = 0.04); however, among those with <100 % adherence, higher adherence was associated with use of one or more adherence devices (coefficient = 7.32; p = 0.003). Our data suggest that adolescents who experienced virologic failure often used adherence devices which may not have been sufficiently effective in optimizing adherence. Therefore, other tailored adherence-enhancing methods need to be considered to maximize virologic suppression and decrease drug resistance and HIV transmission.
Tài liệu tham khảo
Chesney MA. The elusive gold standard. Future perspectives for HIV adherence assessment and intervention. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S149–55.
Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. Aids. 2001;15(9):1181–3.
Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21–30.
Gifford AL, Bormann JE, Shively MJ, Wright BC, Richman DD, Bozzette SA. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr. 2000;23(5):386–95.
Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. New Engl J Med. 2002;347(6):385–94.
Gordillo V, del Amo J, Soriano V, Gonzalez-Lahoz J. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. Aids. 1999;13(13):1763–9.
Silverberg MJ, Leyden W, Horberg MA, DeLorenze GN, Klein D, Quesenberry CP. Older age and the response to and tolerability of antiretroviral therapy. Arch Intern Med. 2007;167(7):684–91.
Ammassari A, Murri R, Pezzotti P, et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr. 2001;28(5):445–9.
Hadland SE, Milloy MJ, Kerr T, et al. Young age predicts poor antiretroviral adherence and viral load suppression among injection drug users. Aids Patient Care STDs. 2012;26(5):274–80.
Martinez J, Harper G, Carleton RA, et al. The impact of stigma on medication adherence among HIV-positive adolescent and young adult females and the moderating effects of coping and satisfaction with health care. Aids Patient Care STDS. 2012;26(2):108–15.
Murphy DA, Sarr M, Durako SJ, et al. Barriers to HAART adherence among human immunodeficiency virus-infected adolescents. Arch Pediatr Adolesc Med. 2003;157(3):249–55.
Murphy DA, Wilson CM, Durako SJ, Muenz LR, Belzer M, Ne AMHAR. Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort in the USA. Aids Care. 2001;13(1):27–40.
Marhefka SL, Farley JJ, Rodrigue JR, Sandrik LL, Sleasman JW, Tepper VJ. Clinical assessment of medication adherence among HIV-infected children: examination of the treatment interview protocol (TIP). Aids Care. 2004;16(3):323–37.
Centers for Disease Control and Prevention. HIV Among Youth. 2013; http://www.cdc.gov/hiv/risk/age/youth/. Accessed June 2013.
Centers for Disease Control and Prevention. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 U.S. dependent areas—2010. HIV Surveillance Supplemental Report 2012; 17 (No. 3, part A); http://www.cdc.gov/hiv/topics/surveillance/resources/reports/. Accessed 9/5/2013.
MacDonell K, Naar-King S, Huszti H, Belzer M. Barriers to medication adherence in behaviorally and perinatally infected youth living with HIV. AIDS Behav. 2013;17(1):86–93.
Saberi P, Yuan P, John M, Sheon N, Johnson MO. A pilot study to engage and counsel HIV-positive African American youth via telehealth technology. Aids Patient Care STDS. 2013;27(9):529–32.
Remien RH, Hirky AE, Johnson MO, Weinhardt LS, Whittier D, Le GM. Adherence to medication treatment: a qualitative study of facilitators and barriers among a diverse sample of HIV+ men and women in four US cities. AIDS Behav. 2003;7(1):61–72.
Biadgilign S, Deribew A, Amberbir A, Deribe K. Barriers and facilitators to antiretroviral medication adherence among HIV-infected paediatric patients in Ethiopia: a qualitative study. Sahara J. 2009;6(4):148–54.
Mills EJ, Nachega JB, Bangsberg DR, et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. Plos Med. 2006;3(11):2039–64.
Hazra R, Siberry GK, Mofenson LM. Growing up with HIV: children, adolescents, and young adults with perinatally acquired HIV infection. Annu Rev Med. 2010;61:169–85.
Koenig LJ, Nesheim S, Abramowitz S. Adolescents with perinatally acquired HIV: emerging behavioral and health needs for long-term survivors. Curr Opin Obstet Gynecol. 2011;23(5):321–7.
Andrade ASA, McGruder HF, Wu AW, et al. A programmable prompting device improves adherence to highly active antiretroviral therapy in HIV-infected subjects with memory impairment. Clin Infect Dis. 2005;41(6):875–82.
Mannheimer SB, Morse E, Matts JP, et al. Sustained benefit from a long-term antiretroviral adherence intervention. Results of a large randomized clinical trial. Jaids-J Acquir Immune Defic Syndr. 2006;43:S41–7.
Safren SA, Hendriksen ES, Desousa N, Boswell SL, Mayer KH. Use of an on-line pager system to increase adherence to antiretroviral medications. Aids Care. 2003;15(6):787–93.
Naar-King S, Wright K, Parsons JT, Frey M, Templin T, Ondersma S. Transtheoretical model and substance use in HIV-positive youth. Aids Care. 2006;18(7):839–45.
Naar-King S, Arfken C, Frey M, Harris M, Secord E, Ellis D. Psychosocial factors and treatment adherence in paediatric HIV/AIDS. Aids Care. 2006;18(6):621–8.
Derogatis LR, Spencer PM. The brief symptom inventory (BSI): administration, and procedures manual-I. Baltimore: Clinical Psychometric Research; 1982.
Knight JR, Shrier LA, Bravender TD, Farrell M, VanderBilt J, Shaffer HJ. A new brief screen for adolescent substance abuse. Arch Pediatr Adolesc Med. 1999;153(6):591–6.
Saberi P, Johnson MO, McCulloch CE, Vittinghoff E, Neilands TB. Medication adherence: tailoring the analysis to the data. AIDS Behav. 2011;15(7):1447–53.
Hosmer DW, Lemeshow S. Applied logistic regression. New York: Wiley; 2000.
Saberi P, Comfort M, Johnson MO. The relationship between daily organization and adherence to antiretroviral therapy: a qualitative perspective. Jaids-J Acquir Immune Defic Syndr. 2012;61(1):E3–6.
Belzer ME, Naar-King S, Olson J, et al. The Use of cell phone support for non-adherent HIV-infected youth and young adults: an initial randomized and controlled intervention trial. Aids Behav. 2014;18(4):686–96.
Outlaw AY, Naar-King S, Tanney M, et al. The initial feasibility of a computer-based motivational intervention for adherence for youth newly recommended to start antiretroviral treatment. Aids Care. 2014;26(1):130–5.
Dowshen N, Kuhns LM, Gray C, Lee S, Garofalo R. Feasibility of interactive text message response (ITR) as a novel, real-time measure of adherence to antiretroviral therapy for HIV+ youth. AIDS Behav. 2013;17(6):2237–43.